A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept (Orencia) in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (LIMIT-JIA)
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Katharine Moore, MD
Study ID
Protocol Number: 19-2020
More information available at ClinicalTrials.gov: NCT03841257
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers